Core Viewpoint - ZYUS Life Sciences Corporation has launched a brokered private placement to raise between C$15 million and C$16 million for the development of its non-opioid drug candidates for pain management [1][5]. Group 1: Offering Details - The private placement consists of a minimum of 23,809,523 units and a maximum of 25,396,825 units, priced at C$0.63 per unit [1]. - Each unit includes one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of an additional common share at C$0.85 for 24 months [2]. - The offering will be conducted on a best-efforts basis by Canaccord Genuity Corp. as the lead agent [3]. Group 2: Financial Terms - A cash commission of 5.0% of the gross proceeds will be paid to the agents, along with warrants equal to 5.0% of the units sold [4]. - Subscriptions from the President's List will incur a reduced commission of 2.5% [4]. - The lead agent will also receive a corporate finance fee of 2.0% of the gross proceeds and warrants equal to 2.0% of the units sold, excluding President's List subscriptions [4]. Group 3: Use of Proceeds - The net proceeds from the offering will be allocated to advance the clinical development of Trichomylin® softgel capsules, including completing the Phase 2a clinical trial and preparing for Phase 2b [5]. Group 4: Regulatory and Listing Information - The units will be offered in all Canadian provinces except Québec and may also be offered in the U.S. under applicable exemptions [6]. - The common shares are listed on the TSX Venture Exchange under the symbol "ZYUS," with the closing of the offering expected around January 29, 2026, pending regulatory approvals [7].

Core Insights - ZYUS Life Sciences Corporation announced favorable preliminary results from its Phase 2a UTOPIA-1 trial, which evaluates Trichomylin® softgel capsules for managing cancer-related pain [1][2] Group 1: Trial Overview - UTOPIA-1 is a single-arm, proof-of-concept study focused on the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain [2] - Preliminary results are based on data from the first 25% of enrolled patients who have completed treatment [2] Group 2: Preliminary Findings - Early data suggest a reduction in average daily pain, pain interference, and pain severity [5] - There was a reduction in opioid dosing for breakthrough pain, indicating potential benefits of Trichomylin® [5] - No serious adverse events related to Trichomylin® softgel capsules were reported, and the capsules were generally well tolerated [5] Group 3: Company Commitment and Future Outlook - The company emphasizes its commitment to developing non-opioid alternatives for pain management and aims to secure regulatory approval for its innovative therapies [3] - The positive preliminary findings reflect over seven years of scientific research and clinical development, reinforcing the potential of Trichomylin® to address cancer-related pain [2][3]

Core Insights - ZYUS Life Sciences Corporation has initiated its Phase 2a UTOPIA-1 clinical trial to evaluate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules for patients with advanced cancer and moderate to severe cancer-related pain [1][2][4] Group 1: Clinical Trial Details - The UTOPIA-1 trial is a single-arm, proof-of-concept study focused on patients suffering from advanced cancer and significant pain [2] - The Centre Hospitalier de l'Université de Montréal (CHUM) has been activated as the first clinical site, with the first patient already enrolled and ongoing recruitment for additional patients [3][4] Group 2: Company Objectives and Commitment - The activation of the first site and patient enrollment is seen as a significant advancement in ZYUS' clinical development program, highlighting the company's commitment to providing non-opioid pain management solutions [3][4] - ZYUS aims to bridge the treatment gap between conventional therapies like opioids and NSAIDs, offering a differentiated, evidence-based approach for managing cancer pain [4] Group 3: Company Overview - ZYUS Life Sciences Corporation is focused on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management, with an emphasis on securing intellectual property and obtaining regulatory approval [5] - The company is dedicated to making a transformational impact on patients' lives through innovative therapies [5]